It was my greatest pleasure to present the 1st Annual meeting of the newly formed Scottish Society of Cytomics (SSC) in Aberdeen, UK as host and SSC chair. The aim of establishing a new technological science group in Scotland is to bring scientists in the field of cytomics from cross technology centres together. Why Cytomics? Actually, the theme of our first SSC meeting already provides the answer -Translational Cytometry from Bench to Bedside-relates to the future of this society and it reflects our shared passion for cellular systems. Cytometry is growing as a diagnostic and monitoring technology in biological research and in the clinical laboratory and therefore it is useful to establish a forum to exchange information, to present research data and to explore new applications of the rapidly expanding technologies of imaging and flow cytometry. To better understand and further explore the cellular systems, the merging and bundling of technologies is necessary. Single technology can't provide the ultimate solution. Therefore, CYTOMICS, which analyzes the functional relationship between cell systems and networks using the "omics" technologies (e.g., Genomics, Proteomics), will give a comprehensive view of a disease. The analysis of already existing data from scientific studies or routine diagnostic procedures makes cytomics a valuable tool for studying diseases, that will be of immediate value in translational medicine. The Scottish Society of Cytomics was formed with the intention of providing information related to the art of cytometry (flow and imaging) including its cross technology applications to genomics, proteomics, in vivo imaging and other core related areas between the research organisations in Scotland and Northern England. We believe that SSC will be the ideal forum for users of cytometry and omics systems to get together, share expertise and innovation, discuss pitfalls, successes and ideas for the future of translational cytomics. It was a great privilege for me to announce the exciting line up of talks, workshop and exhibitions. SSC 2014 brought together top scientists from various disciplines, and international renowned keynote speakers. Further to the oral presentations we were happy with the quality of abstracts submitted by motivated scientists. This poster presentation resulted in poster awards to recognize the excellent research. I would like to take the opportunity to acknowledge the support and generosity of the SSC 2014 sponsors in making this meeting a success. Our special thank goes to Becton Dickinson, Sony, BioStatus and Miltenyi Biotec for their extra donations and contributions. In conclusion this conference brought the rich and rewarding experiences for all of us in science (>150 attendees), and helped to develop friendships. We hope that our Society will be a platform for future success in cytomics research and invite you to participate in these activities. Welcome to our newly formed Scottish Society of Cytomics that hopes to foster a strong network for this scientific community.
Although we often consider pathogens as presenting a single face to the immune system, it is clear that this "golf ball" model of pathogen-host interaction limits our understanding of population dynamics in the host. For example, others have shown that population heterogeneity in surface antigen presentation by Trypanosoma brucei and heterogeneity in the expression of pathogenicity factors by Vibrio harveyi and the human fungal pathogen Candida albicans are required for full virulence of these organisms [1, 2, 3] . This is perhaps counter-intuitive, given a working model in which virulence factor expression is correlated to degree of pathogenicity of a given organism. In this work, we discuss the application of flow cytometry techniques to the analysis of fungal pathogens. Specifically, we examine the impact of environmental fluctuations in nutrient availability on the presentation of cell wall components on the surface of fungal cells and use these features as markers for population heterogeneity. We demonstrate that population heterogeneity can be modulated by environmental conditions such as carbon source availability. We show that heterogeneity is rapidly lost when cells grown in a mixed nutrient environment representative of in vivo conditions are transitioned to the single nutrient conditions more typical of in vitro laboratory culture, and is slow to re-emerge when cells are transitioned back. Moreover, we show that heterogeneity in the presentation of pathogen-associated molecular patterns is similarly modulated by environmental conditions. Together, our observations underscore the potential for population-based analyses in investigating host-pathogen dynamics. The compensation of multiple fluorochromes within the same experiment enables the correct characterization of cell phenotype by the exclusion of any errors associated with fluorochrome spectral overlap. Fluorochrome compensation is far from standardized, from laboratory to laboratory the reagents and rationale to achieve compensation values varies considerably, so an approach is given to standardize the set up procedure, outlining the major reasons for the steps employed. The first step is to recognize that photomultiplier voltages are of equal importance as the compensation controls to achieve correct fluorochrome compensation, therefore we need to adjust the voltages very carefully to minimize amplification of overlapping fluorochromes, hence minimizing the final compensation values, as a consequence the final experiment will be more "stable". To understand how we achieve quality within a clinical flow cytometry setting we need to appreciate the difference between Quality Control (QC) and Quality Assurance (QA). QC may be defined as a procedure or set of procedures intended to ensure that a manufactured product or performed service adheres to a defined set of quality criteria. In contrast QA is the planned and systematic activities implemented in a quality system so that quality requirements for a product or service will be fulfilled. In general, one can look at QA as the overall description and control of a process while QC plays a part in control of the process. When looking at QA we need to consider how we control the pre analytical, analytical and post analytical process. These processes need to be documented and training and competence evidenced. The pre analytical process includes defining the specimen type that is acceptable, how it will be transported, what identification is required and whether this is the correct test for the patient. The analytical process is the part of the process that most scientists are familiar with. We have to ensure that we conduct the test using the correct methodology using suitable equipment (validation) and the reagents are suitable for purpose (verification). As part of the evidence for validation it is normal to refer to reference methods, published guidelines, biological reference material, external and internal QC. The post analytical process, like in the pre analytical process, is where we again have to look at how the laboratory interfaces with it's users. Consideration has to be given to who is competent to interpret reports and advise service users, how we are going to report laboratory results so that the user understands them and finds them an aid to diagnosis and treatment. Flow cytometry, and the more recently introduced imaging flow cytometry, are ideal tools for following the cell cycle in mammalian cells.
One of the first applications of flow cytometry was looking at DNA content via single parameter fluorescence of a DNA-binding dye such as propidium iodide or DAPI but this only provides a snapshot of cells at one point in time. More sophisticated techniques are needed to investigate multiple rounds of division and these include the addition of a nucleotide analog such as bromodeoyurdine (BrdU) which can follow cells through 1-2 rounds of cell division; the BrdU-Hoechst quenching technique which can follow 3-4 rounds of cell division or the use of a dye dilution technique using protein binding dyes such as CFSE or the CellTrace dyes or lipid-binding dyes such as the PKH dyes. We recently developed a method to study cell cycle analysis in multiple rounds of division using a combination of CellTrace Violet for round of division, propidium iodide for DNA content and staining for phoshpoH3 to identify mitotic cells [1] . This enables us to follow cells through up to 6 rounds of cell division. By adding drugs that interfere with the cell cycle either by inhibiting DNA synthesis (etoposide) or that inhibit mitosis (Nocodazol) we are able to look at the effect in cells at a known point in division history without the need for blocking the cells beforehand. This gives a true sense of how individual cells relate to one another. In addition, by using imaging flow cytometry we are able to sub-divide the individual phases of mitosis which can give further information on the action of cell-cycle inhibiting drugs and may allow this method to be used to give mechanistic information of the action of candidate anti-cancer drugs. Cellular therapy is a rapidly growing area of medicine, particularly immune therapies for infection and cancer, as well as therapies that aim to regenerate diseased or damaged tissues. Flow cytometry is one of the most important tools in the development of novel cellular therapeutics. Cellular identity, viability and differentiation status are essential data to be collected and validated throughout the manufacturing process. Flow cytometry is used in characterization of raw starting material; as an inprocess control; to define the final product and also is often an essential tool to monitor responses in treated patients. In this presentation, the technical aspects of whole blood rare cell flow cytometry (such as circulating dendritic cells) were discussed, and how this can be applied to complex cultures of stem cells differentiating into blood cells for therapeutic use. These cultures contain CD45+ stem cells; nucleated RBC; enucleated RBC; as well as free nuclei and debris. Enucleating in vitro RBC could be simply quantified by using staining with CD45, CD235a, DRAQ5 DNA staining and DAPI dead cell exclusion. Staining was performed on raw culture supernatant (as would be performed in a no lyse no wash blood preparation), then diluted before flow cytometry analysis [1] . The other area discussed in this presentation was the improved identification of chemokine receptor expression on cells for therapy by flow cytometry. Chemokines orchestrate the movement and homing of cells in the body. The ability to manipulate the expression of chemokine receptors is a major focus of cellular therapeutics research. In this presentation, the use of biotinylated chemokines tetramerized with streptavidin-fluorochromes was discussed as a method to improve staining of chemokine receptors by flow cytometry. These labelled human ligands stain cells strongly, often more strongly than antibodies, and have the unique advantage that they can be used across species boundaries. Additionally, these reagents can be combined with magnetic bead sorting to isolate chemokine receptor-positive cells with improved in vitro and in vivo migration capacity [1] . Flow cytometric analysis and flow cytometric cell sorting (FACS) have revolutionized the understanding of immune cell biology and proved an indispensible tool not just for immunologists but for those interested in inflammatory processes. Right through from the early days of impedancebased flow cytometry counter devices to the first fluorescence-based flow cytometry instruments where side and forward scatter parameters with one or two florescent color instruments to state-of-the-art multicolour flow cytometric and mass cytometry with over 38-antibody panels, we are discovering new cell types and multiple immune cell phenotypes that exhibit a diverse array of functions. Today most laboratories use flow cytometry as a powerful technique to support their fundamental biological and medical research. Our own work has used flow cytometry to successfully measure mammalian (e.g., human and mouse) leucocyte function (e.g., cell polarization, reactive oxygen species release, shedding of CD62L, upregulation of CD11b, etc) and apoptosis (shedding of CD16 from neutrophils and fluorescently labeled annexin V binding to apoptotic cell surfaces, DNA hyplodiploid peak assessment of permeabilised cells, macrophage efferocytosis (phagocytosis of apoptotic cells and to sort highly pure non-perturbed neutrophils from autofluorescent eosinophils [1] [2] [3] . Furthermore, flow cytometry has been crucial in the identification, characterization and phenotypic analysis of inflammatory leucocytes isolated from healthy volunteers and patients [4] and from cells isolated from various inflammatory sites in mouse models of inflammation [5] . Recent advances in flow cytometry (especially in imaging flow cytometry) will undoubtedly provide further insights and new information in the already complex field of leucocyte biology. There is a growing appreciation of the influence of both the tumour microenvironment and the dynamic nature of the cellular microcommunity in determining tumour progression and therapeutic resistance. Changes in cell heterogeneity, resulting from time-varying changes in the microenvironment, present complex challenges for cancer therapy. For example, the tumour micro-community comprises multiple levels of cellular interactions overlaid with pervading influences such as variation in the levels of oxygenation. Molecular targeting combined with agents that target the microenvironment offer novel approaches. The presentation focused on two examples supported by cytometric techniques. First, dissecting the influences of cellular interactions on tumour progression-related cell behavior. An in vitro, non-adherent small cell lung cancer (SCLC) cell model system enabled the engineering of cellular micro-communities. SCLC cells show surface expression of a potential drug target, polysialylated neural cell adhesion molecule (NCAM; NCAM1 or CD56). The extensive addition of polysialic acid (polySia) to NCAM in SCLC decreases membrane apposition, cell adhesion and enables cell migration. Cytometric studies reveal heterogeneity in the expression of polySia in SCLC cell populations that can be related to proliferation potential both in vitro and in vivo. In constructed 3-D microcommunities, polySia expression was driven in non-expressing variants by the presence of over-expressing subpopulations. This suggests that a degree of homeostasis operates with implications for polySia-NCAMtargeted therapies. The second example addressed the targeting of hypoxia for therapeutic advantage using a novel hypoxia activated prodrug (HAP) technology. Hypoxia in tumour regions, arising from loss of vascularity, generates drug resistant phenotypes. Targeting hypoxic tumour cells using HAPs has been previously attempted using a diverse group of chemicals based mainly on structures with alkylating functionality. Crucially most of these agents are reduced in single electron steps by a number of enzymes including cytochrome P450 reductase. This produces prodrug conversion to species that bind covalently to DNA. Critically, the cytotoxins generated do not persist such that targeted cells upon re-oxygenation may contribute to tumour regrowth. We have developed the concept of a unidirectional hypoxia activated prodrug (uHAP), building upon experience with di-N-oxides of tertiary amine anthraquinones, to develop the novel agent OCT1002. The uHAP represents a distinct class of HAP, reduced to a cytotoxic species through an irreversible two-step process, each involving a two-electron reduction. The bioactive reduction products inhibit DNA processing and topoisomerase II activity, selectively causing cancer cell death. The presentation explored the application of cytometric methods to reveal the mechanisms of action of OCT1002 and to provide an insight into the targeting of hypoxic regions of prostate and pancreatic cancers. The above examples highlight the importance of cell-based approaches in the development of therapeutic strategies that address changing patterns of target presentation in different cellular microenvironments. [PJS acknowledges the contributions of Prof. Rachel Errington (Cardiff University); Prof. Stephanie McKeown (University of Ulster) and Robert Falconer (Bradford University)].
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Deletion of myeloid-PTP1B decreases MHC Class I expression and peptide presentation through an IL-10 dependent mechanism in response to LPS challenge Samantha Le Sommer Protein Tyrosine Phosphatase 1B (PTP1B) inhibition is a target in the treatment of type 2 Diabetes Mellitus, and as such PTP1B inhibitors are in Phase II clinical trials. Previously our laboratory demonstrated that myeloid-specific deletion of PTP1B (LysM PTP1B) results in an increase in systemic IL-10 secretion and expression. In the current work we investigated how PTP1B deficiency affects the activation phenotype of murine macrophages in response to inflammatory stimuli. We demonstrate that myeloid-specific PTP1B deletion results in a decrease in expression of MHC Class I, along with co-stimulatory molecules CD80 and CD40. Interaction assays reveal a defect in the cells' ability to activate reporter B3Z T cells. Myeloid-specific PTP1B deletion increases the percentage of bone-marrow-derived-macrophages (BMDMs) positive for IL-10 which is associated with a decrease in iNOS production. Western blotting analysis demonstrated hyperphosporylation of ERK1/2 which has been suggested before to improve access to the IL-10 promoter. This provides evidence to suggest that myeloid-PTP1B deletion decreases MHC Class I expression and peptide presentation through an IL-10-dependent mechanism. Cell therapy regimens are frequently compromised by low-efficiency cell homing to therapeutic niches. Improvements in this regard would enhance effectiveness of clinically-applicable cell therapy. The major regulators of tissue-specific cellular migration are chemokines and therefore selection of therapeutic cellular populations for appropriate chemokine receptor expression would enhance tissue-homing competence. We have recently shown that biotinylated ligands for chemokine receptors can be used as efficient cell sorting reagents [1] . These ligands have several advantages over antibodies, as they can be chemically synthesized to the appropriate grade for clinical use; produced and modified extremely quickly and are generally not species-specific. Furthermore, receptors are rapidly recycled post cell selection leaving cells free to respond to chemokine gradients, and thereby migrate to the required therapeutic site. We have applied this technology to the improvement of dendritic cell (DC) and T cell products for potential use as cellular therapeutics. CCL19, a high-affinity ligand for CCR7, is of particular interest in this field, as CCR7 expression by DC is a marker of maturity and lymph node homing ability. Also, CCR7
+ central memory T cells are the most desired cell population for generation or engineering of tumour-antigen-specific therapeutic responses. Here we report the generation of biotinylated, chemically synthesised, modified human CCL19 molecules for optimised cell sorting. Our results demonstrate that these ligands allow the efficient enrichment of mature, antigen-loaded human or murine CCR7 + DC using a rapid and established magnetic bead sorting strategy. CCR7 + murine bone marrow-derived DC (BM-DC) isolated using this GMP-compliant method display significantly improved lymphnode homing ability in vivo over standard (unsorted) BM-DC preparations. Using in vitro models, such as murine OT-I, we also demonstrate the ability of these sorted DC to efficiently generate both effector and memory antigen-specific T cell responses. In conclusion, we show that biotinylated ligands for chemokine receptors constitute a novel, GMPcompliant cell sorting strategy that could enhance the efficacy of existing clinical cell therapy regimens. 
P3
Characterisation of a novel vaccine delivery system for livestock Rebecca K. [1] . Material and methods: Transformed human embryonic kidney (293T) cells were transfected with four plasmids which encode the various vector components for the production of lentiviral vectors. Vectors produced so far contain an eGFP reporter cassette to facilitate measurement of infectivity by flow cytometry. Self-inactivating (SIN) vectors have been produced to decrease the probability of the generation of replication-competent virus [2] . To produce a SIN vector, viral enhancers and promoter sequences were deleted by Gibson Cloning leaving expression of transgenes controlled by an internal promoter. Integrase deficient lentiviral vectors were produced by introducing point mutations by PCR on the D,D-35-E motif within the integrase protein to reduce insertional oncogenesis [3] . Results: Stable expression of antigens is important to a successful vaccine, therefore the stability of ovine lentiviral transduction was evaluated over a 4 week period with eGFP-positive cells measured periodically. 50% of cells remained eGFP-positive after 4 weeks in rapidly dividing cells suggesting a sustained, stable transduction. Ovine lentivirus vectors have the ability to infect a wide range of cell types from different species with similar efficiency to the well characterised murine leukaemia virus (MLV) vector. Self-inactivating vectors with non-active LTRs retain the ability to express transgenes in vitro. Integration deficient vectors appear to have to correct phenotype as eGFP-positive cells decreased over time in dividing cells.
Conclusion:
We have created a novel, self-inactivating, integration deficient ovine lentiviral vector which retains the ability to express transgenes in vitro. Future studies will investigate ovine lentiviral vectors mechanisms of immune response in vitro and study their efficiency to deliver appropriate immunity in vivo.
Results: We selected mAB clone 3A4, which was able to recognise CLECSF8 by ELISA and western blot to analyse CLECSF8 expression in the mouse by flow cytometry. While CLECSF8 transcript was widely expressed, CLECSF8 protein expression was predominantly found on monocytes/macrophages and neutrophils within e. g. the peritoneal cavity, blood and bone marrow. Notably, CLECSF8 was expressed only weakly in the lung, but strongly upregulated in a pulmonary Mycobacterium bovis BCG infection model. In vitro, CLECSF8 expression on thioglycollate elicited macrophages was strongly induced upon treatment with TLR agonists or microbial stimuli. In agreement with previous reports, our data suggests that CLECSF8 associates with the signalling adaptor FcRγ. Interestingly, surface expression of CLECSF8 in a murine fibroblast cell line was greatly enhanced by co-transfection of Mincle, but not Dectin-2. Intriguingly, Mincle expression mirrored CLECSF8 expression in our in vitro stimulation experiments. Further analyses on wild-type and CLECSF8
-/-primary macrophages in vitro, or cells harvested after intra-peritoneal and intratracheal instillation of BCG demonstrated a lack of Mincle-upregulation in the absence of CLECSF8. Conclusion: CLECSF8 is a predominantly monocyte/macrophage and neutrophil expressed receptor, showing significant interdependence with Mincle, but not Dectin-2.
Materials and methods: U937 monocyte cells were supplemented with sodium selenite (Na 2 SeO 3 ; 100nM or 200nM) or not and cultured for 48 hours at 37°C. Paraquat (100mM) and S-Nitroso-N-acetyl-DL-penicillamine (10mM) (PQ/SNAP) were added to the cells to induce OS. Cell viability was assessed via MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay while ROS production was determined by Flow Cytometry using the reagent CM-H 2 DC-FDA. Results: PQ/SNAP treatment significantly reduced U937 cell viability and significantly increased ROS generation compared to untreated control U937 cells (p<0.001); confirming the induction of OS. U937 cells cultured in medium containing either 100nM or 200nM Na 2 SeO 3 were significantly less affected by OS. More specifically, 100nM Na 2 SeO 3 supplementation significantly improved cell viability by 33% (p<0.001) and significantly attenuated ROS generation by 32% (p<0.001) when compared to unsupplemented PQ/SNAP treated cells. Additionally, 100nM Na 2 SeO 3 supplementation resulted in a significantly greater increase in cell viability compared to 200nM Na 2 SeO 3 supplementation of PQ/SNAP treated cells (p<0.01).
Conclusions: This study indicates that selenium supplementation may be effective in reducing the detrimental effects of OS by significantly improving cell viability and ROS quenching ability; thus providing preliminary data to support the potential role for selenium supplementation with regards to CVD prevention of overweight/obese individuals.
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The effect of aged erythrocytes and erythrocyte-derived microparticles on lymphomatous and healthy B cells Caitlin Hughes 1 , Mark A.Vickers 1, 2 , Robert N. Barker 1 , Lindsay S. Hall
